Did rates of myocarditis or pericarditis change with the 2024-2025 COVID vaccine formulations?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
Available surveillance and regulatory reports show the 2023–2024 mRNA COVID vaccines had estimated myocarditis/pericarditis incidence of roughly 8 cases per million doses overall and higher rates in young males (about 27–38 per million for males 12–24 or 16–25), and early 2024–2025 vaccine-safety signals are mixed: FDA required updated warnings based on 2023–2024 data [1], while some 2024–2025 trial and post‑market signals suggest lower or no new myocarditis signal for updated formulations [2] [3] [4].
1. What regulators decided and why — a label change, not a panic
In 2025 the FDA required manufacturers to add updated myocarditis/pericarditis language reflecting analyses from the 2023–2024 mRNA formula: about 8 cases per million doses overall in ages 6 months–64 and roughly 27 cases per million in males 12–24; the agency said the highest estimated incidence after the 2023–2024 formula was in males 16–25 (38 per million in one account) and asked firms to revise warnings and fact sheets accordingly [1] [5] [3].
2. How that compares to earlier estimates — risk remains rare
Pre‑2023 surveillance and peer‑reviewed analyses had consistently described myocarditis/pericarditis after mRNA vaccines as rare and concentrated in young males and after the second dose — studies reported a wide range of estimates but generally low absolute rates (examples: 1.2 per 100,000 doses in Canadian reports and meta‑analytic signals of increased relative risk versus unvaccinated) [6] [7]. FDA’s new unadjusted estimate of ~8 per million for 2023–24 sits within that low absolute-risk context [1].
3. Newer formulations (2024–2025) — conflicting early signals
Industry‑sponsored and conference data presented in 2025 reported no myocarditis/pericarditis cases and no troponin signal in a randomized crossover study of Moderna’s updated 2024–25 mRNA vaccine in 12–30‑year‑olds, suggesting the updated formulation may carry less cardiac biomarker signal than original products [2]. At the same time, federal updates and continuing surveillance keep myocarditis/pericarditis on product labels because of the earlier 2023–24 analyses the FDA reviewed [1] [3].
4. What clinicians and public health agencies say — balance risk and benefit
CDC guidance continues to recognize myocarditis/pericarditis as a rare serious adverse event following COVID vaccination, most often in adolescent and young adult males within a week after an mRNA dose, while also emphasizing that COVID infection carries higher cardiac risk; CDC and other clinical groups have adjusted dosing intervals in some populations to lower myocarditis risk [4] [8] [9].
5. Evidence on mechanism and prognosis — emerging science but limited long‑term data
Laboratory and translational work from Stanford and others implicate specific cytokine responses (CXCL10 and IFN‑γ) as potential biological contributors to mRNA‑vaccine‑associated myocarditis and propose mitigation strategies; these mechanistic insights help explain the phenomenon but do not change the rarity of reported events [10] [9] [11]. Longer‑term outcome data are described as generally reassuring in some industry‑linked mid‑term follow‑ups, but available review pieces and commentators note limitations in follow‑up windows and call for standardised case definitions and surveillance [12] [6].
6. Where reporting and interpretation diverge — surveillance complexity
Meta‑analyses and passive-reporting systems differ in findings: pooled observational work shows an elevated relative risk versus unvaccinated populations in some studies (RR ≈2 within 30 days in one meta‑analysis), while passive systems like VAERS and claims databases yield different absolute rates and cannot by themselves prove causation [7] [2]. Media and advocacy outlets have highlighted higher fatality claims or long‑term risks, but these assertions are not corroborated in the peer‑reviewed surveillance summaries cited here and sometimes rest on selective or non‑comparative data [13] [14].
7. Bottom line for patients and policy — rare, monitored, context matters
Current official material places myocarditis and pericarditis as rare risks tied most strongly to young males and to earlier mRNA formulations, and regulators updated labels to reflect 2023–24 data [1] [5]. Early clinical safety data for 2024–25 updated formulations indicate no new signal in some studies, but surveillance continues and recommendations (including spacing doses) are used to further reduce risk [2] [8]. Available sources do not mention definitive long‑term increases attributable to the 2024–2025 formulations beyond ongoing monitoring and label updates (not found in current reporting).
Limitations: this summary uses the supplied reports and press coverage; differing methodologies (passive reporting, claims analyses, randomized trials) produce different numbers, and available sources do not provide a single, definitive rate-change analysis comparing all pre‑ and post‑2024 formulations head‑to‑head (not found in current reporting).